Wave crashes — again — as 2 more drugs go down to defeat, this time for Huntington's
Just seven days ago Roche threw in the towel on their antisense drug for Huntington’s. Now we’re learning that a closely-watched antisense oligonucleotide program in the hands of Wave Life Sciences $WVE crashed in an early-stage study — wiping out two experimental drug candidates and forcing the biotech to turn to a back-up approach while watching shares crater.
WVE-120102 failed to separate from placebo in impact on mutant Huntingtin protein at any of the doses given to Huntington’s patients. And a separate, smaller study showed only an inconsistent hit on mHTT that indicated they were on a one-way track to failure with the drug.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 106,500+ biopharma pros reading Endpoints daily — and it's free.